EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance

Tawfeek A A Yahya, Mustafa A Al-Qadhi

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.109706 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Tawfeek A A Yahya und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a 18084, Yemen. Electronic address: t.alobaidy@su.edu.ye. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Protein Kinase Inhibitors, Drug Design, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 238 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic lymphoma kinase (ALK) is a clinically validated oncogenic driver in multiple malignancies; however, the long-term efficacy of ALK tyrosine kinase inhibitors is frequently compromised by tumor heterogeneity, adaptive signaling, and compensatory pathway activation. Although successive generations of ALK inhibitors have addressed several resistance mutations, achieving durable therapeutic responses remains challenging. In this context, dual-target ALK inhibitors-single molecular entities capable of concurrently inhibiting ALK and complementary oncogenic targets-have emerged as a rational polypharmacological strategy. This review summarizes recent advances (2018-2025) in the rational design of dual ALK inhibitors, highlighting key chemotypes including 2,4-diaminopyrimidines, 2-aminopyridines, and pyrazolo[1,5-a]pyrimidines. Structure-based drug design strategies such as pharmacophore hybridization, scaffold hopping, solvent-front mutation engineering, and macrocyclization are critically analyzed with respect to potency, selectivity, CNS penetration, and resistance coverage. Dual-target combinations involving ALK with TRK, EGFR, ROS1, HDAC, CDK4/6, FAK, and related targets are systematically discussed, supported by SAR trends, crystallographic insights, and molecular modeling. Collectively, this review provides a design-focused framework to guide the development of next-generation dual ALK inhibitors aimed at achieving durable pathway suppression in ALK-driven cancers. Solvent-front mutation engineering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseProtein Kinase InhibitorsDrug DesignDrug Resistance, NeoplasmAntineoplastic AgentsHumansMolecular StructureStructure-Activity RelationshipPyrimidinesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

ALKComputer-aided drug design (CADD)Drug resistanceDual inhibitorsKinase-targeted therapySBDD

Substanzen

Anaplastic Lymphoma KinaseProtein Kinase InhibitorsAntineoplastic AgentsALK protein, humanPyrimidinesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a 18084, Yemen. Electronic address: t.alobaidy@su.edu.ye.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a 18084, Yemen. Electronic address: m777329509@gmail.com.

Zitieren

APA

Yahya, T. A. A., & Al-Qadhi, M. A. (2026). Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109706

Vancouver

Yahya TAA, Al-Qadhi MA. Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109706

BibTeX
@article{Yahya2026,
  author = {Yahya, Tawfeek A A and Al-Qadhi, Mustafa A},
  title = {Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.109706}
}
Kostenlos starten →